BEN-MAIMON CAROLE
President and CEO
BEN-MAIMON CAROLE has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Nov 12, 2026.
On the most recent filing, BEN-MAIMON CAROLE is listed as President and CEO at Larimar Therapeutics, Inc. Inside the rolling window, BEN-MAIMON CAROLE reported 1 open-market purchase totaling $50K in LRMR and no open-market sales.
Companies traded
Other insiders at LRMR
Insider Buying
$50K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has BEN-MAIMON CAROLE made?
BEN-MAIMON CAROLE has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company since 2026.
Which companies does BEN-MAIMON CAROLE trade?
BEN-MAIMON CAROLE has filed SEC Form 4 disclosures for 1 company, including LRMR.
When was BEN-MAIMON CAROLE's most recent SEC Form 4 filing?
BEN-MAIMON CAROLE's most recent SEC Form 4 filing on Tracefour is dated Nov 12, 2026.
What is BEN-MAIMON CAROLE's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, BEN-MAIMON CAROLE is listed as President and CEO.
What is BEN-MAIMON CAROLE's total buy and sell value in the current window?
Inside the rolling retention window, BEN-MAIMON CAROLE bought $50K and sold $0 based on SEC Form 4 filings.
What was BEN-MAIMON CAROLE's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 18,050 LRMR shares on 2026-11-11, worth $50K, per SEC Form 4 filings.